Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD (TEMPO3/4)

This study has been completed.
Sponsor:
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by (Responsible Party):
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT00428948
First received: January 26, 2007
Last updated: February 1, 2013
Last verified: February 2013